中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2014年
20期
1284-1287
,共4页
潘奇%朱凯%陈万勇%张巨波%孙惠川%王鲁%任宁
潘奇%硃凱%陳萬勇%張巨波%孫惠川%王魯%任寧
반기%주개%진만용%장거파%손혜천%왕로%임저
肝细胞肝癌%转录因子Sp1%预后指标%组织芯片
肝細胞肝癌%轉錄因子Sp1%預後指標%組織芯片
간세포간암%전록인자Sp1%예후지표%조직심편
hepatocellular carcinoma%transcription factor Sp1%prognostic factor%tissue chip
目的:通过研究肝癌组织内转录因子Sp1的表达及其与肝癌患者临床病理特征及预后的关系,探讨转录因子Sp1作为肝癌预后预测指标的可行性。方法:对98例根治性切除术的肝细胞肝癌肿瘤组织芯片进行免疫组化检测Sp1的表达情况,分析其与肝癌患者临床病理特征及预后之间的关系。结果:免疫组化结果显示Sp1在肝癌组织中表达明显高于对应正常肝脏组织,在有微血管侵犯的患者中升高尤其明显。进一步分析显示Sp1表达与肝癌患者术后总体生存率呈负相关,而与肝癌患者术后复发率呈正相关。结论:转录因子Sp1在肝癌中明显高表达,可作为肝癌患者预后的独立预测指标。
目的:通過研究肝癌組織內轉錄因子Sp1的錶達及其與肝癌患者臨床病理特徵及預後的關繫,探討轉錄因子Sp1作為肝癌預後預測指標的可行性。方法:對98例根治性切除術的肝細胞肝癌腫瘤組織芯片進行免疫組化檢測Sp1的錶達情況,分析其與肝癌患者臨床病理特徵及預後之間的關繫。結果:免疫組化結果顯示Sp1在肝癌組織中錶達明顯高于對應正常肝髒組織,在有微血管侵犯的患者中升高尤其明顯。進一步分析顯示Sp1錶達與肝癌患者術後總體生存率呈負相關,而與肝癌患者術後複髮率呈正相關。結論:轉錄因子Sp1在肝癌中明顯高錶達,可作為肝癌患者預後的獨立預測指標。
목적:통과연구간암조직내전록인자Sp1적표체급기여간암환자림상병리특정급예후적관계,탐토전록인자Sp1작위간암예후예측지표적가행성。방법:대98례근치성절제술적간세포간암종류조직심편진행면역조화검측Sp1적표체정황,분석기여간암환자림상병리특정급예후지간적관계。결과:면역조화결과현시Sp1재간암조직중표체명현고우대응정상간장조직,재유미혈관침범적환자중승고우기명현。진일보분석현시Sp1표체여간암환자술후총체생존솔정부상관,이여간암환자술후복발솔정정상관。결론:전록인자Sp1재간암중명현고표체,가작위간암환자예후적독립예측지표。
Objective: To explore the clinical significance of transcription factor Sp1 expression in hepatocellular carcinoma (HCC) and association between Sp1 expression and survival in HCC patients. Methods:With the use of immunoreactivity, Sp1 expres-sion and its correlation with other clinicopathological characteristics were examined in a tissue microarray that contains samples from 98 HCC patients. Results:HCC tissues expressed markedly higher levels of Sp1 than did adjacent normal liver tissues. Sp1 expression was closely associated with microvascular invasion, which suggests that HCC with more microvascular invasion is prone to have in-creased Sp1 expression. Overexpression of Sp1 correlates with significantly shorter overall survival and higher recurrence rates in HCC patients after curative resection. Conclusion:Transcription factor Sp1 may be an independent prognostic factor for both overall surviv-al and cumulative recurrence rate.